Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders

benzinga.com/general/biotech/25/05/45347237/novo-nordisks-sogroya-supports-effective-weekly-alternative-to-daily-hormone-therapy-across-three

Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya (somapacitan) in four different but related growth disorder indications, including small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS), and…

This story appeared on benzinga.com, 2025-05-12 13:24:38.
The Entire Business World on a Single Page. Free to Use →